Derived homopiperazine and pharmaceutical composition

 

The present invention relates to a derived homopiperazine formula II, isotope or its pharmaceutically acceptable salt, where R is hydrogen, alkyl, cycloalkyl or benzyl, R1- AMINOPHENYL, nitrophenyl, hydroxyphenyl, alkoxyphenyl or perederina, pyridinoline, piratininga, hyalinella or sochineniia group. Compounds according to the invention are suitable as ligands of nicotinic acetylcholine receptors and can be used for diseases involving the cholinergic system of the Central and peripheral nervous system. 2 C. and 12 C.p. f-crystals, 1 PL.

Description text in facsimile form (see graphic part). T,

Claims

1. Derived homopiperazine represented by the General formula IIits isotopes or its pharmaceutically acceptable salt, where R represents hydrogen, alkyl, cycloalkyl or benzyl; R1represents an AMINOPHENYL, nitrophenyl, hydroxyphenyl, or alkoxyphenyl, or pyridyloxy, pyridazinyl or personilnya group, a heterocyclic group may be substituted by one Il is cycloalkane, alkenone, hydroxy, halogen, CF3tripterocalyx or-CONR2R3where R2and R3independently represent hydrogen or alkyl, or phenyl, which is substituted by nitro, or alkoxy-alkoxy, or thiophenyl or dibenzyl, or piperazinil, pyrrolidinyl, pyridyl, pyrrolyl, indolyl, or R1represents hyalinella or athinodorou group.

2. Derived homopiperazine under item 1, where R1is a 3-nitrophenyl, 3-AMINOPHENYL, 3-methoxyphenyl or 3-hydroxyphenyl.

3. Derived homopiperazine under item 2, which is 4-methyl-1-(3-nitrophenyl)-homopiperazine, 1-(3-nitrophenyl)-homopiperazine, 1-(3-AMINOPHENYL)-homopiperazine, 1-(3-methoxyphenyl)-homopiperazin or 1-(3-hydroxyphenyl)-homopiperazin, or its pharmaceutically acceptable salt of the merger.

4. Derived homopiperazine under item 1, where R1represents 3-pyridyl, 5-methoxy-3-pyridyl, 5-chloro-3-pyridyl, 5-(4-methyl-1-piperazinil)-3-pyridyl, 5-ethoxy-3-pyridyl, 6-methoxy-3-pyridyl, 5-propoxy-3-pyridyl, 5-phenyl-3-pyridyl, 5-(2-methyl-propyloxy)-3-pyridyl, 5-propyl-1-EN-oxy-3-pyridyl, 6-(N-pyrrolidinyl)-3-pyridyl, 6-phenyl-3-pyridyl, 5-(3-nitrophenyl)-3-pyridyl, 5-butoxy-3-pyridyl, 5-mediaproxy-3-pyridyl, 5-hexyloxy-3-pyridyl, 5-cyclohexylmethoxy-3-pyridyl, 5-(2-ethoxy-ethoxy)-3-pyridyl, 5-pentyloxy-3-pyridyl, 5-heptyloxy-3-pyridyl, 5-(propyl-1-EN-oxy)-3-pyridyl, 5-dibenzyl-3-pyridyl, 5-carboxyamide-3-pyridyl, 5-thiophenyl-3-pyridyl, 5-(3-pyridyl)-3-pyridyl, 5-(1-pyrrolyl)-3-pyridyl, 5-(1-indolyl)-3-pyridyl, 5,6-dimethoxy-3-pyridyl, 5-adenylate-3-pyridyl, 5-cyclopentyloxy-3-pyridyl, 5-(ethoxy-d5)-3-pyridyl, 3-chloro-5-pyridyl, 3-bromo-5-pyridyl, 5-hydroxy-3-pyridyl, 5-tripterocalyx-3-pyridyl, 5-ethinyl-3-pyridyl, 5-trifluoromethyl-3-pyridyl, 6-bromo-3-pyridyl or 6-chloro-3-pyridyl.

5. Derived homopiperazine under item 4, which is 4-methyl-1-(3-pyridyl)-homopiperazine, 1-(5-methoxy-3-pyridyl)-4-methyl-homopiperazine, 1-(5-ethoxy-3-pyridyl)-4-methyl-homopiperazine, 4-methyl-1-(5-phenyl-3-pyridyl)-homopiperazine,
1-(5-butoxy-3-pyridyl)-4-methyl-homopiperazin,
1-(5-methoxyethoxy-3-pyridyl)-4-methyl-homopiperazin,
4-methyl-1-[5-(2-methyl-propyloxy)-3-pyridyl] -homopiperazine,
1-(5-cyclopropylmethoxy-3-pyridyl)-4-methyl-homopiperazin,
4-methyl-1-(5-propyloxy-3-pyridyl)-homopiperazine,
1-(5-hexyloxy-3-pyridyl)-4-methyl-homopiperazin,
4-methyl-1-[5-(3-methyl-butoxy)-3-pyridyl] -homopiperazine,
1-(5-cyclohexylmethoxy-3-pyridyl)-4-methyl-goop,
4-methyl-1-(5-propyl-1-EN-oxy-3-pyridyl)-homopiperazine,
4-methyl-1-(5-dibenzyl-3-pyridyl)-homopiperazine,
4-methyl-1-[5-(3-pyridyl)-3-pyridyl] -homopiperazine,
1-(5-cyclopentyloxy-3-pyridyl)-4-methyl-homopiperazin,
4-benzyl-1-(3-pyridyl)-homopiperazine,
4-ethyl-1-(3-pyridyl)-homopiperazine,
1-(3-pyridyl)-homopiperazine,
1-(6-methoxy-3-pyridyl)-homopiperazine,
1-[6-(N-pyrrolidinyl)-3-pyridyl] -homopiperazine,
1-(6-phenyl-3-pyridyl)-4-homopiperazin,
1-[5-(3-nitrophenyl)-3-pyridyl] -4-homopiperazin,
1-(5-methoxy-3-pyridyl)-homopiperazine,
1-(5-phenyl-3-pyridyl)-homopiperazine,
1-(5-ethoxy-3-pyridyl)-homopiperazine,
1-(5-butoxy-3-pyridyl)-homopiperazine,
1-(5-methoxyethoxy-3-pyridyl)-homopiperazine,
1-[5-(2-methyl-propoxy)-3-pyridyl] -homopiperazine,
1-[5-(3-methyl-butoxy)-3-pyridyl] -homopiperazine,
1-(5-cyclopropylmethoxy-3-pyridyl)-homopiperazine,
1-(5-propyloxy-3-pyridyl)-homopiperazine,
1-(5-hexyloxy-3-pyridyl)-homopiperazine,
1-(5-cyclohexylmethoxy-3-pyridyl)-homopiperazine,
1-[5-(2-ethoxy-ethoxy)-3-pyridyl] -homopiperazine,
1-(5-pentyloxy-3-pyridyl)-homopiperazine,
1-(5-heptyloxy-3-pyridyl)-homopiperazine,
1-[5-(propyl-1-EN-oxy)-3-pyridyl] -homopiperazine,
1-(5-dibenzyl-3-pyridyl)-homopiperazine)-3-pyridyl] -homopiperazine,
1-[5-(3-pyridyl)-3-pyridyl] -homopiperazine,
1-(5-(1-pyrrolyl)-3-pyridyl)-homopiperazine,
1-(5-(1-indolyl)-3-pyridyl)-homopiperazine,
1-(5,6-dimethoxy-3-pyridyl)-homopiperazine,
1-(5-adenylate-3-pyridyl)-homopiperazine,
1-(5-cyclopentyloxy-3-pyridyl)-homopiperazine,
1-[(5-ethoxy-d5)-3-pyridyl] -homopiperazine,
1-(3-chloro-5-pyridyl)-homopiperazine,
1-(3-bromo-5-pyridyl)-homopiperazine,
1-(5-hydroxy-3-pyridyl)-homopiperazine,
1-(5-trifloromethyl-hydroxy-3-pyridyl)-homopiperazine,
1-(5-ethinyl-3-pyridyl)-homopiperazine,
1-(5-trifluoromethyl-3-pyridyl)-homopiperazine,
1-(6-bromo-3-pyridyl)-homopiperazine or
1-(6-chloro-3-pyridyl)-homopiperazine,
or its pharmaceutically acceptable salt of the merger.

6. Derived homopiperazine under item 1, where R1represents a 6-chloro-3-pyridazinyl, 6-phenyl-3-pyridazinyl, 6-methyl-3-pyridazinyl or 3-pyridazinyl.

7. Derived homopiperazine under item 6, which is 4-methyl-1-(6-chloro-3-pyridazinyl)-homopiperazine, 4-methyl-1-(6-phenyl-3-pyridazinyl)-homopiperazine, 4-methyl-1-(3-pyridazinyl)-homopiperazine, 4-methyl-1-(6-methyl-3-pyridazinyl)-homopiperazine, 1-(6-chloro-3-pyridazinyl)-homopiperazin, 1-(6-phenyl-3-pyridazinyl)-homopiperazine, 1-(6-methyl-3-pyridazinyl)-homopiperazin homopiperazine by p. 1, where R1represents a 6-chloro-2-pyrazinyl or 3,6-dimethyl-2-pyrazinyl.

9. Derived homopiperazine under item 8, which is 1-(6-chloro-2-pyrazinyl)-homopiperazin or 1-(3,6-dimethyl-2-pyrazinyl)-homopiperazin, or its pharmaceutically acceptable salt of the merger.

10. Derived homopiperazine under item 1, where R1is a 3-chinoline or 4-ethenolysis.

11. Derived homopiperazine under item 10, which represents a 1-(4-ethenolysis)-homopiperazin, or its pharmaceutically acceptable salt of the merger.

12. Pharmaceutical composition having properties modulators Nikonovich acetylcholine receptors containing a therapeutically effective amount of a compound according to any one of paragraphs. 1-11 or its pharmaceutically acceptable salts joining together with at least one pharmaceutically acceptable carrier or diluent.

13. The pharmaceutical composition according to p. 12, prepared for local introduction to the epidermis as ointments, creams or lotions, or as a transdermal patch.

14. The compound according to any one of paragraphs. 1-11 for use as drugs for the treatment of a disease of a living animal body, including a human, which Chu is AKAM:
Items 1,4,5, 12-14 - have priority 27.10.1997, 24.03.1998, 19.06.1998, 27.10.1998 (PCT) for different values of radicals and connections specified in those paragraphs.

Paragraphs 2 and 3 have priority from 19.06.1998 and 27.10.1998, for different values of radicals and connections specified in those paragraphs.

Paragraphs 6-9 and 11 priority 27.10.1998 (PCT).

Paragraph 10 priority 27.10.1997 and 24.03.1998.

 

Same patents:

The invention relates to a derivative of 1,2,4-thiadiazole, substituted in the 5-position of General formula I, in which X Is N; R1- C1-6alkyl; R2is hydrogen, R3, R4and R5each independently selected from hydrogen; trifloromethyl;is Ar2, Ar2CH2or Het2; AG2is phenyl; Het2is a monocyclic heterocycle selected from thiadiazolyl, pyridinyl, pyrimidinyl or pyrazinyl, their N-oxide forms, the pharmaceutically acceptable acid additive salts and stereochemical isomeric forms

The invention relates to derivatives of 1-(N-phenyliminomethyl)piperazine of the formula I, where R is H, alkyl -, cycloalkyl-substituted cycloalkyl-WITH or monocyclic heteroaryl-CO; R1Is h or lower alkyl; R2- halogen, alkoxy, phenoxy, NO2, CN, acyl, NH2, NH(acyl), alkyl-SO2NH, alkoxycarbonyl, NH2WITH, (alkyl)NHCO (alkyl)2NCO, (acyl)NHCO, CF3or polyporaceae; benzyl or mono - or bicyclic aryl, or heteroaryl, all of which are optionally substituted

The invention relates to new substituted pyrazolylborate General formula (I) in which R1-R6have the meanings given in the description of the invention

The invention relates to a method for producing derivatives of imidazole of formula A, where R1represents a substituted heterocycle, R4is phenyl, optionally substituted, R2represents the алкилN3, -(CR10R20)nOR9further as stated in the description

The invention relates to billnum compounds or substituted pyridinium formula (I), where X denotes N or CR8where R8denotes hydrogen, halogen, phenyl, alkyl, alkoxy, alkoxycarbonyl, carboxy, formyl or-NR4R5where R4and R5denote hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, naphthyl; R1aand R1Brepresent trifluoromethyl, alkyl, alkenyl, quinil, cycloalkyl, alkanoyl; R2denotes alkyl, alkenyl, quinil, cycloalkyl; R3denotes hydroxy, TRIFLUOROACETYL, alkanoyl, alkenyl; AG denotes an aromatic or heteroaromatic ring, for example phenyl, naphthyl, pyridyl, furanyl, thiophenyl

The invention relates to new arylpyrimidines compounds of formula I having the effect of antagonist 5HT2B-receptor, and pharmaceutical compositions

The invention relates to vysokomernoa tritium 2-methyl-4-(4-methyl-1-piperazinil)-10H-thieno[2,3-b] [1,5] benzodiazepine, which can be used

The invention relates to new pyrimidine derivative of General formula (I) or their pharmaceutically acceptable salts, with high antisecretory activity with the properties of reversible proton pump inhibitor that can be used to obtain valuable medicines

The invention relates to a derivative of isoindoline formula I, where Y denotes oxygen or H2one of R1and R2represents halogen, alkyl, alkoxy, alkylamino, dialkylamino, cyano or carbarnoyl, second from R1and R2represents hydrogen, halogen, alkyl, alkoxy, alkylamino, dialkylamino, cyano or carbarnoyl, R3represents hydrogen, alkyl or benzyl

The invention relates to a derivative of 1,2,4-thiadiazole, substituted in the 5-position of General formula I, in which X Is N; R1- C1-6alkyl; R2is hydrogen, R3, R4and R5each independently selected from hydrogen; trifloromethyl;is Ar2, Ar2CH2or Het2; AG2is phenyl; Het2is a monocyclic heterocycle selected from thiadiazolyl, pyridinyl, pyrimidinyl or pyrazinyl, their N-oxide forms, the pharmaceutically acceptable acid additive salts and stereochemical isomeric forms

The invention relates to new divanillyltetrahydrofuran F.-ly (I)

< / BR>
where Y denotes CH or N; R1- halogen or CF3; R2and R3is hydrogen, n = 0 or 1; Ph1and Ph2is phenyl unsubstituted or substituted with halogen, CF3or (C1-C4- alkoxyl and their salts

The invention relates to crystalline polymorphic forms of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6] cyclohepta[1,2-b] pyridine
Up!